atopic dermatitis

sailing boat water yacht ocean wind
Biotech

Windward breezes toward phase 3 with $165M for TSLP ambitions

The cash infusion is meant to accelerate the development of the company’s lead candidate, a twice-yearly anti-TSLP antibody, into phase 3.
Angus Liu May 4, 2026 10:31am
Sanofi headquarters Sanofi

Sanofi bispecific sees respiratory ph. 2 wins, eczema fail

Apr 7, 2026 4:10am
Metallic arrow symbols illuminated by blue and magenta lights forming a graph on blue and magenta background

Connect’s Dupixent rival hits the mark in phase 3 eczema trial

Mar 30, 2026 9:32am
target reach ladder climb meet win beat competition

Apogee data drive hype as threat to Lilly, Sanofi becomes clear

Mar 23, 2026 9:00am
target reach ladder climb meet win beat competition

Pfizer ramps up plans for trispecific after ph. 2 eczema win

Mar 9, 2026 9:10am
warning sign

New cancer cases prompt Kyowa to shutter rocatinlimab trials

Mar 3, 2026 11:00am